Free tool
FAERS Monitor: Fabhalta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218276 or its brand name (Fabhalta, Iptacopan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
800
Serious
392
49% of reports
Hospitalization
193
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache89
- fatigue62
- haemoglobin decreased56
- pyrexia56
- nausea49
- diarrhoea44
- drug ineffective44
- product dose omission issue39
- breakthrough haemolysis37
- off label use35
- pneumonia34
- rash32
- vomiting32
- asthenia29
- dizziness29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 259 |
| 2025 | 327 |
| 2026 | 207 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,359 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breakthrough haemolysisSignal | 37 | 2689.8 | 1931.6 | 87,806 |
| haemoglobin decreasedSignal | 56 | 14.3 | 11.1 | 685 |
| pyrexiaSignal | 56 | 4.3 | 3.3 | 138 |
| headacheSignal | 89 | 3.7 | 3.1 | 181 |
| product dose omission issueSignal | 39 | 3.5 | 2.6 | 68 |
| pneumoniaSignal | 34 | 2.8 | 2.0 | 37 |
| fatigueSignal | 62 | 2.1 | 1.6 | 36 |
| astheniaSignal | 29 | 2.0 | 1.4 | 14 |
| rash | 32 | 1.9 | 1.4 | 14 |
| diarrhoea | 44 | 1.8 | 1.3 | 15 |
| vomiting | 32 | 1.8 | 1.3 | 11 |
| nausea | 49 | 1.6 | 1.2 | 12 |
| dizziness | 29 | 1.5 | 1.1 | 5 |
| off label use | 35 | 1.1 | 0.8 | 0 |
| drug ineffective | 44 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.